Vitro S.A. sells Cytognos to BD to prioritize the market launch of their new and disruptive Molecular Biology and Anatomic Pathology diagnostic platforms
Cytognos divestment is a first strategic step aimed at positioning Vitro as a new worldwide diagnostic player in their key market segments SEVILLE, Spain, Feb. 4, 2022 /PRNewswire/ -- Vitro S.A, (www.vitro.bio) a privately held company headquartered in Seville, Spain, announced today the sale of Cytognos to Becton Dickinson and Company (BD). Cytognos is a company specializing in flow...
Invitation to the presentation of Elekta’s third quarter 2021/22
STOCKHOLM, Feb. 4, 2022 /PRNewswire/ -- Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the third quarter 2021/22 at 10:00 a.m. CET on February 24. The interim report for the third quarter will be published at 7:30 a.m. CET on the same day. The company's development will be presented by Elekta's President and CEO Gustaf Salford together...
Nanoform signs GMP manufacturing program with TargTex following formulation success
HELSINKI, Feb. 4, 2022 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, today announced it has signed a GMP1 manufacturing program (clinical development) to enhance TargTex's Glioblastoma multiforme drug candidate. The program starts with a PoP (Proof of Process) phase. This follows a successful PoC (Proof of Concept) study where the hydrogel formulation developed by Nanoform (CESS®2 technology-based nanoparticles) enabled...
NCCN Joins the Call to ‘Close the Care Gap’ on World Cancer Day
Global nonprofit National Comprehensive Cancer Network participates in annual awareness day, highlighting cancer care disparities and free resources to help, detailed at NCCN.org/wcd. PLYMOUTH MEETING, Pa., Feb. 4, 2022 /PRNewswire/ -- World Cancer Day is observed every February 4. This year, the National Comprehensive Cancer Network® (NCCN®) is joining organizations worldwide to...
New Zealand’s Medsafe Grants Provisional Approval for Novavax’ COVID-19 Vaccine
Nuvaxovid™ is the first protein-based COVID-19 vaccine to receive provisional approval for distribution in New Zealand GAITHERSBURG, Md., Feb. 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted provisional approval...
USANA’s Malaysia and Korea markets start 2022 with major honors
SALT LAKE CITY, Feb. 4, 2022 /PRNewswire/ -- USANA's international markets have started off the new year with two major awards. USANA Korea was presented the 'family-friendly company' certification selected by the Ministry of Gender Equality and Family, while Citta Bella Magazine awarded USANA Malaysia for its Celavive Vitalizing Serum. To find...
Wolters Kluwer Lauded by Frost & Sullivan for Enabling Aligned Decision-making with Its Clinical Decision Support Solutions
SAN ANTONIO, Feb. 3, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the North American clinical decision support (CDS) industry, and based on its findings, recognizes Wolters Kluwer with the 2021 North America Company of the Year Award. The company delivers its solutions - UpToDate®, Lexicomp®, Emmi®, and Medi-Span® Sentri7® and POC Advisor™ - to help clinicians minimize the risk...
LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology
SEOUL, South Korea, Feb. 3, 2022 /PRNewswire/ -- LISCure Biosciences ("LISCure") announced that it had reached an agreement with The Scripps Research Institute ("Scripps Research") to collaboratively research on bacteria-mediated immuno-oncology candidates against multiple cancer types. Scripps Research is the top nonprofit scientific institute in the US for producing high-quality research...
Medicines and Healthcare Products Regulatory Agency Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine in Great Britain*
Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted)▼ is the first protein-based COVID-19 vaccine authorized in Great Britain Novavax and the U.K. Vaccines Taskforce previously announced an agreement for up to 60 million doses Authorization based on data including an ongoing pivotal Phase 3 trial conducted in the U.K. with almost...
Mentice publishes the company’s year-end report for the period January-December 2021
STOCKHOLM, Feb. 3, 2022 /PRNewswire/ -- Continued strength with net sales growth above 30% despite the pandemic Fourth quarter (October-December 2021) Order intake amounted to 73.7 (73.1) MSEK. Net sales amounted to 67.7 (45.9) MSEK. Operating income for the period before depreciations (EBITDA) totalled 12.0 (4.3) MSEK. Net income for the period amounted to...
